证券代码：301263 证券简称：泰恩康 广东泰恩康医药股份有限公司投资者关系活动记录表 编号：投-008 □ 特定对象调研 □ 分析师会议 投资者关系活动 □ 媒体采访 □ 业绩说明会 类别 □ 新闻发布会 □ 路演活动 □ 现场参观 √ 其他（电话会议） 兴证全球基金、中邮创业基金、中欧基金中海基金、建信基金、 嘉实基金、嘉合基金、汇添富基金、淡水泉投资、民生信托、中 庚基金、长信基金、野村资管、阳光资产、循远资产、信达证券、 信达证券、相聚资本西部证券、泰康资产、格物资本、前海云溪 基金、申万证券、申九资产、禧弘私募基金、潼骁投资、混沌投 资、和谐汇一、山西证券、睿扬投资、平安基金、民生证券、昆 参与单位名称及 仑健康保险、康曼德资本、凯石基金、玖歌投资、金信基金、汇 人员姓名 百川、华西证券、华西基金、华泰证券、华福医药、华创证券、 华安医药、红马投资、弘毅远方基金、禾永投资、海通证券、恒 立私募基金、国泰基金、国盛证券、国君证券、广发证券、格林 基金、复星集团、方正证券、敦和资产、东吴证券、德邦证券、 北信瑞丰基金、北京泽铭投资、安信基金 （以上排名不分先后） 时间 2023年10月29日（星期日） ...

Financial Performance - The company's revenue for Q3 2023 was ¥176,003,932.82, a decrease of 11.40% compared to the same period last year[5]. - Net profit attributable to shareholders for Q3 2023 was ¥32,768,283.09, down 33.94% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was ¥30,006,851.53, a decline of 34.23% compared to the previous year[5]. - The basic earnings per share for Q3 2023 was ¥0.08, reflecting a decrease of 33.33% year-on-year[5]. - The weighted average return on equity was 1.81%, down 0.97% from the previous year[5]. - In the first three quarters of 2023, the company achieved operating revenue of CNY 581.10 million, a year-on-year increase of 1.34%[16]. - The net profit attributable to shareholders of the listed company was CNY 141.82 million, representing a year-on-year growth of 11.53%[16]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 131.48 million, up 9.92% year-on-year[16]. - Total operating revenue for the period reached CNY 581,096,360.27, an increase of 1.16% compared to CNY 573,432,365.02 in the previous period[27]. - Net profit attributable to shareholders of the parent company was CNY 141,821,132.18, representing an increase of 11.59% from CNY 127,158,475.24 in the previous period[28]. - The total comprehensive income for the period was CNY 136,909,204.91, an increase from CNY 127,739,140.77 in the previous period[29]. Assets and Liabilities - Total assets at the end of Q3 2023 amounted to ¥2,111,527,680.16, an increase of 3.57% from the end of the previous year[5]. - As of September 30, 2023, total assets amounted to CNY 2.11 billion, an increase from CNY 2.04 billion at the beginning of the year[22][24]. - The company's current assets decreased to CNY 1.26 billion from CNY 1.53 billion at the beginning of the year[24]. - Total liabilities amounted to CNY 259,212,465.77, up from CNY 184,843,822.55 in the previous period[26]. - The company’s non-current liabilities increased to CNY 67.53 million from CNY 28.52 million[25]. Cash Flow - The net cash flow from operating activities decreased by 47.73% year-to-date, totaling ¥50,727,763.58[5]. - Operating cash flow net amount was CNY 50,727,763.58, a decrease of 47.8% compared to CNY 97,054,451.32 in the previous period[32]. - The net cash flow from investing activities for Q3 2023 was -241,266,653.55, compared to -701,921,527.74 in the same period last year[33]. - The net cash flow from financing activities was -120,113,632.95, a significant decrease from 893,059,310.56 in Q3 2022[33]. - The total cash and cash equivalents at the end of Q3 2023 amounted to 496,111,118.52, up from 425,768,948.36 at the end of Q3 2022[33]. - The net increase in cash and cash equivalents for Q3 2023 was -310,625,268.08, contrasting with an increase of 288,199,555.88 in Q3 2022[33]. Shareholder Information - The company reported a total of 10,734 ordinary shareholders at the end of the reporting period[11]. - The top shareholder, Zheng Hanjie, holds 20.77% of the shares, totaling 88,378,020 shares[11]. - The company plans to repurchase shares worth between CNY 12.50 million and CNY 25.00 million to boost investor confidence[21]. Research and Development - The company increased its R&D investment, which contributed to the decline in overall profitability during the reporting period[9]. - The company increased R&D investment to CNY 61.90 million in the first three quarters of the year, a year-on-year growth of 85.80%[18]. - Research and development expenses increased significantly to CNY 49,112,983.45, up 94.73% from CNY 25,220,770.88 in the previous period[28]. - The innovative drug CKBA ointment received approval for Phase II clinical trials for vitiligo in July 2023, with patient enrollment expected to commence soon[18][20]. - The company is expanding its product pipeline, with new treatments for male prostate hyperplasia and hair loss expected to submit NDA applications by the end of the year[18]. Product Development and Marketing - Sales revenue from sexual health medications reached CNY 201.45 million, an increase of 18.96% compared to the same period last year[17]. - Sales revenue from gastrointestinal medications was CNY 135.40 million, a year-on-year increase of 34.24%[17]. - Sales revenue from ophthalmic medications was CNY 132.75 million, a decrease of 4.05% year-on-year[17]. - The company is confident in establishing "He Wei Zheng Chang Wan" as a well-known brand in the domestic acute gastrointestinal medication sector[17]. - The production line upgrade for "He Wei Zheng Chang Wan" has been completed, and supply has resumed, with expectations for rapid sales growth[17]. - The company plans to enhance the promotion of its ophthalmic product "Wo Li Ting" to achieve growth[17]. - The company is actively advancing the domestic production and nationwide promotion of "He Wei Zheng Chang Wan"[17]. - The company signed a technology transfer contract with Thailand Liwanshan Pharmaceutical in July 2023, acquiring full production technology for "Hewei Zhengchang Wan," enhancing its OTC product portfolio[19]. Other Information - The company has not undergone an audit for the Q3 2023 report[34]. - The new accounting standards were first implemented in 2023, affecting the financial statements[34].

证券代码：301263 证券简称：泰恩康 公告编号：2023-067 广东泰恩康医药股份有限公司 关于与上海市第一人民医院签署技术转让合同的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 本次交易存在履约风险、医疗器械注册风险，具体请见本公告"六、本次交易的风险提 示"，敬请广大投资者注意投资风险。 一、交易概述 1、2023 年 10 月 28 日，广东泰恩康医药股份有限公司（以下简称"公司"或 "甲方"）与上海市第一人民医院（以下简称"乙方"）签署《技术转让合同》（以 下简称"合同"），公司拟受让取得上海市第一人民医院拥有的免疫年龄诊断试剂 盒相关专利及技术（以下简称"本次交易"）。本次技术转让费用总额为人民币 5,000 万元，同时甲方按合同约定支付合同产品销售提成。双方同意在免疫年龄 诊断试剂盒研发方面开展排他性的合作，此外乙方在不影响其正常诊疗、科研与 教学活动的情况下，将免疫年龄诊断试剂盒检测项目纳入乙方的体检项目，并作 为甲方免疫年龄诊断试剂盒产品的定点检测机构，同时积极协助甲方在上海市区 域医院中推广使用免疫年龄诊断试剂盒 ...

证券代码：301263 证券简称：泰恩康 公告编号：2023-065 广东泰恩康医药股份有限公司 关于部分董事及高级管理人员增持公司股份计划 时间过半的进展公告 董事、副总经理陈淳先生，董事、董事会秘书、副总经理李挺先生，财务 总监周桂惜女士保证向本公司提供的信息内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 特别提示： 广东泰恩康医药股份有限公司（以下简称"公司"）董事、副总经理陈淳先 生，董事、董事会秘书、副总经理李挺先生，财务总监周桂惜女士（以下简称"增 持主体"）计划自 2023 年 7 月 25 日起 6 个月内合计增持金额不低于人民币 1,250 万元且不超过人民币 2,500 万元（均含本数），本次增持计划不设置增持股份价 格区间。具体内容详见公司于 2023 年 7 月 24 日披露的《关于部分董事及高级管 理人员增持公司股份计划的公告》（公告编号：2023-054）。 公司于近日收到上述增持主体出具的《关于增持公司股份计划进展的告知 函》，截至本公告披露日，增持计划时间已过半，增持主体合计通过深圳证券交 易所 ...

证券代码：301263 证券简称：泰恩康 公告编号：2023-064 广东泰恩康医药股份有限公司 关于收到公司控股股东、实际控制人、董事长提议 回购公司股份的提示性公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 广东泰恩康医药股份有限公司（以下简称"公司"）近日收到公司控股股东、 实际控制人、董事长郑汉杰先生出具的《关于提议广东泰恩康医药股份有限公司 回购公司股份的函》。郑汉杰先生提议公司使用自有资金通过深圳证券交易所交 易系统以集中竞价交易方式回购公司已发行的部分人民币普通股（A 股）股票， 具体情况如下： 一、提议人的基本情况及提议时间 1、提议人：公司控股股东、实际控制人、董事长郑汉杰先生； 2、是否享有提案权：是； 3、提议时间：2023 年 10 月 25 日。 二、提议回购股份的原因和目的 基于对公司未来发展的信心和对公司价值的认可，为有效维护广大股东利 益，增强投资者信心，同时建立完善公司长效激励机制，充分调动公司员工的积 极性，有效地将股东利益、公司利益和员工利益紧密结合在一起。结合公司自身 情况，郑汉杰先生提议公司使用自有资金回购公司已发 ...

证券代码:301263 证券简称:泰恩康 公告编号:2023-062 本公司及董事会全体成员保证公告内容的真实、准确和完整,没有虚假记 载、误导性陈述或者重大遗漏。 为进一步加强与投资者的交流沟通,广东泰恩康医药股份有限公司(以下简 称"公司")将参加由广东证监局和广东上市公司协会共同举办的"2023 广东 辖区上市公司投资者网上集体接待日"活动,现将有关事项公告如下: 本次投资者网上集体接待日活动将采取网络远程的方式举行,投资者可以登 录"全景路演"网站(https://rs.p5w.net)参与公司本次投资者网上集体接待日活 动,活动时间为 2023 年 9 月 19 日(星期二)15:45 至 17:00。 届时,公司董事长、总经理郑汉杰先生,公司董事、副总经理兼董事会秘书 李挺先生,财务总监周桂惜女士将通过网络互动形式,与投资者就公司经营情况 及发展战略等方面进行沟通与交流。欢迎广大投资者积极参与。 特此公告。 广东泰恩康医药股份有限公司 董事会 2023 年 9 月 14 日 广东泰恩康医药股份有限公司 关于参加 2023 广东辖区上市公司投资者网上 集体接待日活动的公告 ...

广东泰恩康医药股份有限公司 关于全资子公司收到药品注册受理通知书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 证券代码：301263 证券简称：泰恩康 公告编号：2023-063 广东泰恩康医药股份有限公司（以下简称"公司"）全资子公司山东华铂 凯盛生物科技有限公司于近日收到国家药品监督管理局（以下简称"国家药监 局"）签发的巴瑞替尼片境内生产药品注册上市许可申请《受理通知书》，国 家药监局根据《中华人民共和国行政许可法》第三十二条的规定，对上述药品 的药品注册申请进行了审查，决定予以受理。现将相关情况公告如下： 一、申请注册药品的基本情况 受理号：CYHS2302467 药品名称：巴瑞替尼片 申请事项：境内生产药品注册上市许可 许可药品注册分类：化学药品 4 类 规格：2mg 申请人：山东华铂凯盛生物科技有限公司 审核结论：根据《中华人民共和国行政许可法》第三十二条的规定，经审 查，决定予以受理。 二、药品相关情况简介 三、同类药品情况 经查询国家药监局网站数据，截至目前，巴瑞替尼片未有国内企业获得药 品注册批件。 四、对公司的影响及风险提示 根据国 ...

证券代码：301263 证券简称：泰恩康 公告编号：2023-061 广东泰恩康医药股份有限公司 关于对控股子公司增资的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 一、交易概况 广东泰恩康医药股份有限公司（以下简称"公司"）于 2023 年 8 月 25 日 召开第四届董事会第二十一次会议审议通过了《关于对控股子公司增资的议 案》，根据控股子公司江苏博创园生物医药科技有限公司（以下简称"博创 园"）的发展需要，公司与博创园及其少数股东签署了《关于江苏博创园生物医 药科技有限公司之增资协议》，公司以自有或自筹资金出资人民币 15,000 万元 对博创园进行增资，其中 998.625 万元计入注册资本，14,001.375 万元计入资本 公积，增资完成后公司将持有博创园 60.7278%股权。博创园少数股东均自愿放 弃本次新增注册资本的优先认购权。具体内容详见公司于 2023 年 8 月 29 日披 露于巨潮资讯网（http://www.cninfo.com.cn）的《关于对控股子公司增资的公 告》（公告编号：2023-060）。 二、交易进展情况 近 ...

证券代码：301263 证券简称：泰恩康 广东泰恩康医药股份有限公司投资者关系活动记录表 | --- | --- | |----------------|--------------------| | | □ 特定对象调研 □ | | 投资者关系活动 | □ 媒体采访 □ | | 类别 | □ 新闻发布会 □ | | | □ 现场参观 | | | √ 其他（电话会议） | 中邮基金、汇添富基金、淡水泉、格林基金、东方红资产管理公司、 华泰证券、中国国际金融股份有限公司资管、国泰基金管理有限公 司、广东泓屹资产管理有限公司、德邦证券股份有限公司、北京润 晖资产管理有限公司、Haitong International、信达医药、国君医药、 盘京、民生证券、华安证券、民生证券、方正证券、华西证券、珠 参与单位名称及 海横琴智合远见、西部证券、歌斐诺宝（上海）资产管理有限公司、 人员姓名 长盛基金管理有限公司、华创证券、摩根士丹利华鑫基金、进门财 经、北京金百镕投资管理有限公司、和谐汇一、长盛基金管理有限 公司、国盛证券、中银国际证券有限公司、上海禧弘私募基金管理 有限公司、海通证券、北京金百镕投资管理有限公司 （以 ...

Financial Performance - The company reported a total revenue of RMB 425 million for the first half of 2023, representing a year-on-year increase of 15%[18]. - The company's operating revenue for the reporting period was ¥405,092,427.45, an increase of 8.09% compared to the same period last year[19]. - Net profit attributable to shareholders was ¥109,052,849.09, representing a growth of 40.61% year-over-year[19]. - The net profit after deducting non-recurring gains and losses was ¥101,472,993.80, up 37.13% from the previous year[19]. - In the first half of 2023, the company achieved operating revenue of CNY 405.09 million, a year-on-year increase of 8.09%[59]. - The net profit attributable to shareholders reached CNY 109.05 million, up 40.61% year-on-year, while the net profit after deducting non-recurring gains and losses was CNY 101.47 million, reflecting a growth of 37.13%[59]. Assets and Liabilities - The total assets of the company reached RMB 1.2 billion as of June 30, 2023, showing a growth of 10% compared to the previous year[18]. - Total assets at the end of the reporting period were ¥2,052,427,293.32, a slight increase of 0.67% from the end of the previous year[19]. - Current assets decreased to CNY 1,268,253,815.28 from CNY 1,533,074,014.08, representing a decline of approximately 17.3%[199]. - Total liabilities increased to CNY 230,705,196.35 from CNY 184,843,822.55, indicating a rise of about 24.8%[200]. Research and Development - The company aims to enhance its R&D capabilities, with an investment of RMB 50 million planned for new drug development in 2023[18]. - The company established three major pharmaceutical R&D technology platforms to enhance core competitiveness, focusing on functional excipients, biopharmaceuticals, and generic drug development[28]. - The company has a total of 34 major self-developed pharmaceutical projects, with 7 projects having submitted drug registration applications and 1 project approved for Phase II clinical trials[63]. - The company invested CNY 36.29 million in R&D during the reporting period, marking a significant year-on-year increase of 79.14%[63]. Market Expansion and Product Development - The company plans to expand its market presence by launching three new products in the second half of 2023, targeting a 20% increase in market share[18]. - The company is exploring potential mergers and acquisitions to strengthen its product portfolio and expand its market reach[18]. - The company has submitted registration applications for 7 new drugs and has one drug approved for Phase II clinical trials, indicating a strong pipeline for future growth[28]. - The company has established a strategic partnership with a leading biotech firm to accelerate the development of innovative therapies[18]. Share Capital and Dividends - The company has completed a capital increase, with total shares rising from 236,387,500 to 425,497,500, reflecting a 80% increase in share capital[18]. - The company has not declared any cash dividends or stock bonuses for the reporting period, focusing on reinvestment strategies[4]. - The total share capital increased from 236,387,500 shares to 425,497,500 shares after a capital reserve conversion of 189,110,000 shares, representing an increase of 79.99%[179]. Environmental Responsibility - The company has implemented measures to ensure compliance with environmental standards, including waste gas, wastewater, noise, and solid waste management[128]. - The company has engaged in investor communications regarding its future development plans and operational performance[118]. - The company reported a significant reduction in pollutant emissions, with dust emissions from the production process being as low as 0.065 tons per year, and a discharge rate of 0.027 kg/h, meeting the relevant air quality standards[135]. Risks and Challenges - The company is facing risks related to industry policy changes and market demand for new drug approvals, which may impact future performance[3]. - The company emphasizes the importance of R&D investment to mitigate risks associated with drug registration failures[110]. - The stability of agency operations is crucial for the company's revenue and profit, with potential risks from supplier negotiations[113]. Corporate Governance and Compliance - The company has established a robust internal control system to protect the interests of shareholders, particularly small and medium-sized investors, ensuring financial stability and asset security[139]. - There were no significant non-operating fund occupations by controlling shareholders or related parties during the reporting period[150]. - The semi-annual financial report was not audited, indicating a potential area for future scrutiny[152].